INR 698.8
(3.55%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 1.83 Billion INR | 25.0% |
2022 | 1.38 Billion INR | -37.25% |
2021 | 2.21 Billion INR | 23.81% |
2020 | 1.78 Billion INR | 63.55% |
2019 | 1.08 Billion INR | 55.03% |
2018 | 724.67 Million INR | 219.0% |
2017 | 266.81 Million INR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | 672.35 Million INR | 3.81% |
2024 Q1 | 625.42 Million INR | 12.27% |
2023 Q1 | 474.09 Million INR | -16.84% |
2023 Q4 | 555.04 Million INR | 24.58% |
2023 Q3 | 445.53 Million INR | 30.2% |
2023 Q2 | 342.19 Million INR | -27.82% |
2023 FY | - INR | 25.0% |
2022 Q4 | 570.07 Million INR | 243.27% |
2022 Q3 | 166.07 Million INR | -69.33% |
2022 Q2 | 541.47 Million INR | 61.14% |
2022 Q1 | 336.02 Million INR | -56.95% |
2022 FY | - INR | -37.25% |
2021 Q2 | 971.04 Million INR | 458.33% |
2021 FY | - INR | 23.81% |
2021 Q1 | 173.92 Million INR | -73.22% |
2021 Q4 | 780.58 Million INR | 78.14% |
2021 Q3 | 438.18 Million INR | -54.88% |
2020 Q3 | 301.58 Million INR | 0.0% |
2020 FY | - INR | 63.55% |
2020 Q4 | 649.38 Million INR | 115.33% |
2019 FY | - INR | 55.03% |
2018 FY | - INR | 219.0% |
2017 FY | - INR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Biocon Limited | 41.52 Billion INR | 95.579% |
Blue Jet Healthcare Limited | 2.29 Billion INR | 19.916% |
Concord Biotech Limited | 4.65 Billion INR | 60.598% |
Dishman Carbogen Amcis Limited | 3.07 Billion INR | 40.238% |
Jubilant Ingrevia Limited | 4.56 Billion INR | 59.779% |
Lyka Labs Limited | 167.58 Million INR | -995.395% |
Panacea Biotec Limited | -47.58 Million INR | 3958.262% |
Piramal Pharma Limited | 13.05 Billion INR | 85.939% |
SMS Lifesciences India Limited | 349.41 Million INR | -425.389% |
Syngene International Limited | 10.84 Billion INR | 83.076% |
TAKE Solutions Limited | -1.05 Billion INR | 274.695% |
Zota Health Care Limited | 82.07 Million INR | -2136.742% |